Jeremy (Jez) Maiden Acquires 1,855 Shares of Smith & Nephew plc (LON:SN) Stock

Smith & Nephew plc (LON:SN - Get Free Report) insider Jeremy (Jez) Maiden acquired 1,855 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were purchased at an average cost of GBX 1,070 ($14.29) per share, for a total transaction of £19,848.50 ($26,503.54).

Smith & Nephew Stock Performance

Shares of SN stock traded down GBX 13 ($0.17) on Wednesday, hitting GBX 1,067.50 ($14.25). The company had a trading volume of 1,953,695 shares, compared to its average volume of 343,671. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The stock has a market cap of £11.70 billion, a price-to-earnings ratio of 38.43, a P/E/G ratio of 0.46 and a beta of 0.62. The company's fifty day moving average price is GBX 1,057.98 and its 200-day moving average price is GBX 1,026.05.

Smith & Nephew Increases Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be paid a dividend of $0.23 per share. This represents a yield of 1.61%. The ex-dividend date of this dividend is Thursday, March 27th. This is an increase from Smith & Nephew's previous dividend of $0.14. Smith & Nephew's dividend payout ratio (DPR) is currently 104.41%.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,180 ($15.76) target price on shares of Smith & Nephew in a research report on Tuesday, January 14th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.